4551 KENNEDY COMMERCE DR., HOUSTON, TX
Announces First Patient Treated in Off-the-Shelf Program
Corporate Presentation August 26, 2025 NASDAQ: MRKR
Changing the Company's Accountant
Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
Shareholder votes
Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
Annual Report to Security Holders
Reports Year-End 2024 Corporate and Financial Results
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Initial Statement of Beneficial Ownership
Prospectus filed pursuant to Rule 424(b)(7)